Novo Nordisk Collaborates with OpenAI to Accelerate Drug Development

The pharmaceutical sector has historically been characterized by slow, costly, and uncertain innovation cycles. Creating a single drug can easily take more than a decade, and it requires billions of dollars in investment with no certain return. Novo Nordisk’s new deal with OpenAI represents a shift not only in tools but also mindset. Artificial intelligence is no longer being treated as an add-on, it’s becoming crucial to how new drugmakers do business.  This partnership comes at a time when the demand for obesity and diabetes treatments is increasing worldwide, and competition among the leading pharmaceutical companies is getting intense. Novo […]